Abstract:Due to the elevated fatality rate of cardiovascular diseases, myocardial fibrosis emerges as a prominent pathological alteration in the majority of heart ailments and their associated pathologies, thereby augmenting the likelihood of sudden cardiac death. Consequently, the prompt and obligatory identification of myocardial fibrosis assumes paramount importance in averting malignant incidents among patients afflicted with cardiac disorders. Herein, with higher expression osteopontin (OPN) found in cardiac fibrosis tissue, we have developed a dual-modality imaging probe, namely OPN targeted nanoparticles (OPN@PFP-DiR NPs), which loaded perfluoropentane (PFP) for ultrasound (US) and 1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide (DiR) for near-infrared fluorescence (NIR) of molecular imaging, to investigate the molecular features of cardiac fibrosis using US and NIR imaging. Subsequently, the OPN@PFP-DiR NPs were administered intravenously to a mouse model of myocardial infarction (MI). The US and NIR molecular imaging techniques were employed to visualize the accumulation of the nanoparticles in the fibrotic myocardium. Hence, this research presents a valuable noninvasive, cost-effective, and real-time imaging method for evaluating cardiac fibrosis, with promising clinical applications.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop a non - invasive molecular imaging method for the early detection of myocardial fibrosis. Specifically, the researchers designed a dual - modal imaging probe - OPN - targeted nanoparticles (OPN@PFP - DiR NPs) for osteopontin (OPN) which is over - expressed in myocardial fibrosis. These nanoparticles are loaded with perfluoropentane (PFP) for ultrasound imaging (US) and the near - infrared fluorescent dye DiR for near - infrared fluorescence imaging (NIR), aiming to explore the molecular characteristics of myocardial fibrosis through US and NIR imaging techniques. ### Research Background - Myocardial fibrosis is a significant pathological change in various heart diseases and is closely related to malignant arrhythmia, heart failure and sudden death. - Currently, commonly used imaging techniques such as CT, ultrasound (US), magnetic resonance imaging (MRI), etc. have limitations in detecting myocardial fibrosis, such as insufficient spatial resolution and inability to distinguish between active fibrogenesis and stable scars. - Therefore, developing new imaging strategies, especially techniques that can provide high - resolution images, are non - invasive, economical and sensitive, is crucial for the early detection of myocardial fibrosis. ### Research Objectives - Develop a dual - modal imaging probe (OPN@PFP - DiR NPs) based on OPN - targeting, using ultrasound and near - infrared fluorescence imaging techniques to achieve early and accurate detection of myocardial fibrosis. - Verify the effectiveness and safety of this probe through a mouse myocardial infarction model. ### Main Methods - **Synthesis and Characterization**: Synthesize OPN@PFP - DiR NPs using the two - step emulsification method and the carbodiimide method, and characterize their morphology, particle size and Zeta potential by transmission electron microscopy (TEM), scanning electron microscope (SEM) and laser particle size analyzer. - **In vitro Experiments**: Evaluate the NIR and US imaging capabilities of OPN@PFP - DiR NPs, as well as their cytotoxicity and targeting efficiency. - **In vivo Experiments**: Through a mouse myocardial infarction model, evaluate the NIR and US imaging capabilities and biocompatibility of OPN@PFP - DiR NPs in vivo. ### Expected Results - Successfully develop a non - invasive, cost - effective, real - time myocardial fibrosis imaging method with potential clinical application value. - By early detecting myocardial fibrosis, it helps prevent the occurrence of malignant events and provides support for the identification of drug targets. ### Conclusion This study proposes an innovative dual - modal imaging probe that can effectively detect myocardial fibrosis, providing a new tool for the early diagnosis and treatment of cardiovascular diseases.

A non-invasive osteopontin-targeted phase changeable fluorescent nanoprobe for molecular imaging of myocardial fibrosis